Nothing Special   »   [go: up one dir, main page]

PL2508170T3 - Liposom zawierający irynotekan lub jego chlorowodorek i metoda jego otrzymywania - Google Patents

Liposom zawierający irynotekan lub jego chlorowodorek i metoda jego otrzymywania

Info

Publication number
PL2508170T3
PL2508170T3 PL09851784T PL09851784T PL2508170T3 PL 2508170 T3 PL2508170 T3 PL 2508170T3 PL 09851784 T PL09851784 T PL 09851784T PL 09851784 T PL09851784 T PL 09851784T PL 2508170 T3 PL2508170 T3 PL 2508170T3
Authority
PL
Poland
Prior art keywords
irinotecan
liposome
hydrochloride
preparation
Prior art date
Application number
PL09851784T
Other languages
English (en)
Inventor
Xinyong Tong
Guofeng Lei
Chengxia Yu
Liang Chen
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of PL2508170T3 publication Critical patent/PL2508170T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
PL09851784T 2009-12-03 2009-12-03 Liposom zawierający irynotekan lub jego chlorowodorek i metoda jego otrzymywania PL2508170T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09851784.0A EP2508170B1 (en) 2009-12-03 2009-12-03 Liposome of irinotecan or its hydrochloride and preparation method thereof
PCT/CN2009/075298 WO2011066684A1 (zh) 2009-12-03 2009-12-03 伊立替康或盐酸伊立替康脂质体及其制备方法

Publications (1)

Publication Number Publication Date
PL2508170T3 true PL2508170T3 (pl) 2015-12-31

Family

ID=44114598

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09851784T PL2508170T3 (pl) 2009-12-03 2009-12-03 Liposom zawierający irynotekan lub jego chlorowodorek i metoda jego otrzymywania

Country Status (22)

Country Link
US (2) US20120282325A1 (pl)
EP (1) EP2508170B1 (pl)
JP (1) JP5645954B2 (pl)
KR (2) KR20120089754A (pl)
CN (1) CN102271659B (pl)
AU (1) AU2009356132B2 (pl)
BR (1) BR112012012151B8 (pl)
CA (1) CA2782911C (pl)
CY (1) CY1116811T1 (pl)
DK (1) DK2508170T3 (pl)
ES (1) ES2547698T3 (pl)
HK (1) HK1159482A1 (pl)
HR (1) HRP20150911T1 (pl)
HU (1) HUE027467T2 (pl)
MX (1) MX2012005775A (pl)
PL (1) PL2508170T3 (pl)
PT (1) PT2508170E (pl)
RU (1) RU2526114C2 (pl)
SI (1) SI2508170T1 (pl)
SM (1) SMT201500245B (pl)
WO (1) WO2011066684A1 (pl)
ZA (1) ZA201203316B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102935066B (zh) * 2011-08-16 2014-09-17 齐鲁制药有限公司 一种伊立替康脂质体制剂及其制备方法
KR102024836B1 (ko) 2011-10-21 2019-09-24 셀라토 파마슈티칼즈, 인코포레이티드 동결건조된 리포좀
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
CA2869984C (en) * 2012-04-10 2021-08-17 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CN102697720B (zh) * 2012-06-29 2014-01-15 海南灵康制药有限公司 盐酸伊立替康脂质纳米粒注射剂
CN103181898B (zh) * 2012-11-23 2016-03-09 杭州师范大学 一种奥沙利铂脂质体及其应用
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
JP6251385B2 (ja) 2014-04-30 2017-12-20 富士フイルム株式会社 リポソーム組成物及びその製造方法
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP2017008047A (ja) * 2015-06-25 2017-01-12 参天製薬株式会社 注射剤
SI3337467T1 (sl) 2015-08-20 2021-03-31 Ipsen Biopharm Ltd. Ash Road Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
US20170049775A1 (en) 2015-08-21 2017-02-23 Merrimack Pharmaceuticals, Inc. Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
JP6941606B2 (ja) 2015-10-16 2021-09-29 イプセン バイオファーム リミティド 安定化カンプトテシン医薬組成物
KR102524115B1 (ko) 2016-02-09 2023-04-20 썬 파마슈티컬 인더스트리스 리미티드 관류 시스템
CN107281102A (zh) * 2016-04-11 2017-10-24 江苏竞诺择生物医药科技有限公司 一种用于结直肠肿瘤治疗的药物微粒组合物
CN107456456A (zh) * 2016-06-03 2017-12-12 江苏恒瑞医药股份有限公司 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途
CN118416082A (zh) * 2016-06-28 2024-08-02 应急生物防御行动兰辛有限责任公司 布林西多福韦的制剂
CN106109415B (zh) * 2016-07-26 2019-01-29 金华市人民医院 一种载喜树碱类抗肿瘤药物脂质体、制备方法及其应用
KR20190067172A (ko) 2016-09-09 2019-06-14 아이리시스, 인크. 리포좀 항암 조성물
TWI749091B (zh) * 2016-10-28 2021-12-11 法商施維雅藥廠 脂質體調配物
WO2018083470A1 (en) 2016-11-02 2018-05-11 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
US10722465B1 (en) * 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
JP7364561B2 (ja) 2018-06-20 2023-10-18 富士フイルム株式会社 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
CN109675047B (zh) * 2019-01-07 2020-12-04 中国科学院化学研究所 一种对具有游离羟基的化合物进行脂质体修饰的方法
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US12195755B2 (en) 2019-05-20 2025-01-14 Brown University Placental lipid bilayer for cell-free molecular interaction studies
US11273124B2 (en) * 2019-05-23 2022-03-15 Brown University Antifungal nanoparticles for targeted treatment of fungal infections
CN114177278A (zh) * 2021-10-18 2022-03-15 山东多美康生物医药有限公司 脂质体制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
DK1121102T3 (da) * 1998-09-16 2003-08-11 Alza Corp Liposomindesluttede topoisomeraseinhibitorer
JP4555569B2 (ja) * 2001-11-13 2010-10-06 セレーター ファーマシューティカルズ， インコーポレイテッド 増強された血中安定性を有する脂質キャリア組成物
CN107811971B (zh) * 2004-05-03 2021-10-29 益普生生物制药公司 用于药物输送的脂质体
UA85099C2 (en) * 2004-06-01 2008-12-25 Кабусики Кайся Якулт Хонса Liposomal irinotecan preparation
CN1326525C (zh) * 2004-11-26 2007-07-18 复旦大学 10－羟基喜树碱长循环脂质体及其冻干制剂
US20090148506A1 (en) * 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
US7489990B2 (en) * 2006-07-17 2009-02-10 Fehr Stephen L Systems and methods for calculating and predicting near term production cost, incremental heat rate, capacity and emissions of electric generation power plants based on current operating and, optionally, atmospheric conditions
CN101019834A (zh) * 2006-12-31 2007-08-22 西安力邦医药科技有限责任公司 注射用7－乙基－10羟基喜树碱脂质体的制备方法
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
AU2008227852B2 (en) 2007-03-19 2011-02-24 Fresenius Kabi Oncology Ltd. Proliposomal and liposomal compositions
CN101283983A (zh) * 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物

Also Published As

Publication number Publication date
CY1116811T1 (el) 2017-03-15
CN102271659A (zh) 2011-12-07
ZA201203316B (en) 2013-11-27
WO2011066684A1 (zh) 2011-06-09
US20120282325A1 (en) 2012-11-08
EP2508170A4 (en) 2014-01-15
CA2782911C (en) 2016-08-23
JP5645954B2 (ja) 2014-12-24
SI2508170T1 (sl) 2015-12-31
ES2547698T3 (es) 2015-10-08
RU2526114C2 (ru) 2014-08-20
KR101780915B1 (ko) 2017-09-21
EP2508170B1 (en) 2015-07-29
HRP20150911T1 (hr) 2015-10-23
MX2012005775A (es) 2012-06-13
AU2009356132A1 (en) 2012-06-21
BR112012012151B1 (pt) 2021-01-19
US20170189392A1 (en) 2017-07-06
BR112012012151A2 (pt) 2016-04-12
AU2009356132B2 (en) 2015-01-22
CA2782911A1 (en) 2011-06-09
RU2012123875A (ru) 2014-01-20
SMT201500245B (it) 2015-10-30
HUE027467T2 (en) 2016-10-28
KR20120089754A (ko) 2012-08-13
PT2508170E (pt) 2015-10-16
KR20160140992A (ko) 2016-12-07
HK1159482A1 (en) 2012-08-03
EP2508170A1 (en) 2012-10-10
DK2508170T3 (en) 2015-09-21
US10022365B2 (en) 2018-07-17
JP2013512262A (ja) 2013-04-11
CN102271659B (zh) 2013-09-18
BR112012012151B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
ZA201203316B (en) Liposome of irinotecan or its hydrochloride and preparation method thereof
EP2431023A4 (en) FLEXIBLE LIPOSOME FROM RESVERATROL AND METHOD OF MANUFACTURING THEREOF
IL225961A0 (en) Liposomal nanoparticles and a method for their preparation
EP2463371A4 (en) CONJUGATE AND METHOD FOR PREPARING SIRNA
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
EP2657188A4 (en) FLUOROGRAPHIC AND METHOD FOR PREPARING THE SAME
HK1205108A1 (en) Preparation method of nalmefene hydrochloride dihydrate
AP3048A (en) Agomelatine hydrohalide complex and preparation method thereof
IL258239A (en) and st–methods producing polymorphs of 246 for their preparation
HK1212923A1 (zh) 分泌的 及其抑制方法
GB2471553B (en) Microparticles and method of making microparticles
EP2451816A4 (en) CRYSTALLINE FORM OF PRASUGREL HYDROBROMIDE AND PROCESS FOR PREPARING THE SAME
EP2396763A4 (en) METHOD FOR PROVIDING A GAME AND SYSTEM THEREFOR
EP2394979A4 (en) INTERMEDIATE OF CILASTATIN AND METHOD FOR PREPARING THE SAME
ZA201204133B (en) Health-beneficial preparation and production method
ZA201203060B (en) Composition and method of delivery
EP2610257A4 (en) DIIMIDED DERIVATIVE OF BERBAMINE, MANUFACTURING METHOD AND ITS USE
GB2488494B (en) Solution, use and method of preparation thereof
GB0920642D0 (en) Anchor and methods
GB201013715D0 (en) Pillows and method of manufacturing
EP2467375A4 (en) FORMS OF DEXLANDSOPRAZOLE AND METHOD OF MANUFACTURING THEREOF
EP2404891A4 (en) PROCESS FOR THE PREPARATION OF ACYLBENZENES
GB201002278D0 (en) composition and method of preparation
PL389953A1 (pl) Zakwas orkiszowo-owsiany oraz sposób przygotowania zakwasu orkiszowo-owsianego
HK1174620A1 (zh) 吲唑基取代的二氫異噁唑並吡啶及其使用方法